Objective To discuss the BRAF V600E mutation rate in papillary thyroid carcinoma (PTC) and its relationship with the clinicopathological features. Methods Two hundred and sixty-five PTC patients (including 226 cases of classical type, 29 cases of follicular type, 3 cases of high cell type, 2 cases of diffuse sclerosis type, 2 cases of eosinophilic type, 3 cases of cystic type) from August 2014 to October in Shanxi Provincial Cancer Hospital, were collected with completely clinical and pathological information. The BRAF V600E mutation was detected by real-time polymerase chain reaction (RT-PCR) method. Pearson χ 2 test and the exact probability method were used to analysis the relationship between gene mutations and clinicopathological data. Results BRAF V600E mutation rate in PTC patients was 73.21% (194/265). There was no significant difference in the mutation rate of BRAF V600E among patients with different age, gender, tumor location, tumor number and extravaginal invasion (all P > 0.05), but the mutation rates of BRAF V600E gene in patients with different tumor size, histopathological subtypes, lymph node metastasis and clinical stage were significantly different (all P < 0.05). Conclusion The PTC patients with positive BRAF V600E mutation have poor clinicopathological features, and BRAF V600E mutation may be a predictor of advanced PTC. Key words: Thyroid neoplasms; Carcinoma, papillary; BRAF V600E mutation; Polymerase chain reaction